Hot Flashes: Labs, Causes, and Next Steps

What Causes Hot Flashes?

Hot flashes arise from estrogen-withdrawal-driven instability in the hypothalamic thermoregulatory center, narrowing the thermoneutral zone so that small temperature fluctuations trigger a heat-dissipation response. The cascade involves elevated norepinephrine and activation of neurokinin B (NKB) signaling through KNDy neurons in the arcuate nucleus. Estrogen decline is the dominant trigger, but several other pathways produce identical symptoms.

Menopausal and Perimenopausal Causes

Natural perimenopause accounts for the majority of cases. Estrogen levels begin fluctuating 4 to 8 years before the final menstrual period, and the Study of Women's Health Across the Nation (SWAN) tracked 3,302 women over 15 years and found that the median total duration of frequent vasomotor symptoms was 7.4 years. Women who were premenopausal at symptom onset had the longest duration, averaging 11.8 years.

Surgical menopause from bilateral oophorectomy produces abrupt estrogen withdrawal and is associated with more severe vasomotor symptoms than natural menopause. A 2019 Mayo Clinic Proceedings analysis found women who underwent bilateral oophorectomy before age 46 reported significantly higher hot flash severity scores compared with age-matched women in natural menopause.

Non-Menopausal Causes That Must Be Ruled Out

Not every hot flash comes from ovarian estrogen decline. Thyroid dysfunction, particularly hyperthyroidism, mimics vasomotor symptoms almost exactly. Thyroid-stimulating hormone (TSH) testing is therefore included in every standard hot-flash workup.

Other causes include:

• Carcinoid tumors (flushing driven by serotonin and histamine release)
• Pheochromocytoma (episodic catecholamine surges)
• Lymphoma-related night sweats
• Medication side effects from tamoxifen, raloxifene, GnRH agonists like leuprolide, and certain antidepressants
• Poorly controlled diabetes causing hypoglycemia-triggered diaphoresis

Each of these has a distinct lab fingerprint, which is why a targeted panel matters before starting any treatment.

What Labs Should Be Ordered for Hot Flashes?

A focused lab panel confirms menopausal status, excludes endocrine mimics, and establishes a pre-treatment baseline. Order these tests fasting, on day 2 or 3 of the menstrual cycle when cycle tracking is still possible.

Core Hormone Panel

FSH and LH. Follicle-stimulating hormone above 40 IU/L on two measurements at least 4 to 6 weeks apart, combined with amenorrhea for 12 consecutive months, confirms primary ovarian insufficiency or menopause. The Endocrine Society's 2015 Primary Ovarian Insufficiency guideline specifies the 40 IU/L threshold and the 4-to-6-week retest interval to reduce false positives from perimenopause-related FSH fluctuation.

Estradiol (E2). Postmenopausal estradiol typically falls below 30 pg/mL. Values between 30 and 100 pg/mL during perimenopause can fluctuate widely day to day, so a single low result is not diagnostic. Paired FSH elevation with low E2 supports the diagnosis.

Testosterone (total and free). Relevant in women with concurrent low libido, fatigue, or reduced muscle mass. ACOG Practice Bulletin 141 notes that testosterone declines roughly 50% between ages 20 and 45 independent of menopausal status.

Thyroid and Metabolic Screen

TSH. A TSH below 0.4 mIU/L suggests hyperthyroidism as a hot flash driver. The American Thyroid Association's 2016 guidelines recommend TSH as the single best initial screening test for thyroid dysfunction.

Fasting glucose and HbA1c. Hypoglycemic episodes produce diaphoresis and warmth that patients describe as hot flashes. Fasting glucose above 126 mg/dL or HbA1c at or above 6.5% on two occasions meets the ADA 2024 diagnostic criteria for diabetes.

CBC with differential. Lymphoma-related night sweats are accompanied by constitutional symptoms, but a baseline CBC catches unexpected cytopenias or lymphocytosis before initiating hormone therapy.

Optional Extended Panel

When clinical history suggests carcinoid or pheochromocytoma, add 24-hour urine 5-HIAA, plasma or urine metanephrines, and chromogranin A. These tests carry low yield in a typical perimenopausal woman without episodic hypertension, flushing preceded by headache, or diarrhea, so order them selectively rather than routinely.

Pre-treatment baseline labs before starting hormone therapy should include a fasting lipid panel, basic metabolic panel, and blood pressure measurement. The Menopause Society (formerly NAMS) 2022 Hormone Therapy Position Statement specifies these baselines to individualize cardiovascular risk assessment before prescribing systemic estrogen.

When Should You Worry About Hot Flashes?

Most hot flashes in women aged 45 to 55 are menopausal. Specific red-flag patterns warrant urgent evaluation: onset before age 40, accompanying hypertension spikes, diarrhea and wheezing, drenching night sweats with unexplained weight loss, or hot flashes in men.

Red Flags That Require Prompt Workup

Hot flashes in men are almost always drug-induced or caused by androgen deprivation therapy for prostate cancer. Androgen deprivation therapy produces vasomotor symptoms in 50 to 80% of men receiving it, and the pathophysiology mirrors estrogen withdrawal in women via hypothalamic NKB dysregulation.

Episodic flushing accompanied by a blood pressure rise above 200/110 mmHg should trigger same-day plasma metanephrine measurement to exclude pheochromocytoma, a rare but surgically correctable cause. The Endocrine Society's 2014 pheochromocytoma guideline recommends plasma free metanephrines as the first-line biochemical test due to their 97% sensitivity.

Hot Flashes and Cardiovascular Risk

Vasomotor symptoms are not merely uncomfortable. The SWAN study linked frequent hot flashes in early perimenopause to greater subclinical atherosclerosis, measured as carotid intima-media thickness, independent of traditional cardiovascular risk factors. Women with early-onset frequent hot flashes may benefit from earlier lipid screening and blood pressure monitoring regardless of hormone therapy decisions.

Evidence-Based Treatments for Hot Flashes

Treatment selection depends on symptom severity, contraindications to estrogen, and patient preference. Options range from lifestyle modification for mild symptoms to systemic hormone therapy for moderate-to-severe symptoms.

Hormone Therapy: Most Effective Option

Systemic estrogen therapy is the standard of care for moderate-to-severe vasomotor symptoms in women without contraindications. A 2017 Cochrane review of 23 randomized trials (N=3,429) found that estrogen reduced hot flash frequency by 75% and severity scores by 87% compared with placebo.

The Menopause Society 2022 Position Statement states: "For women aged younger than 60 years or within 10 years of menopause onset without contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms." This guidance directly addresses the timing hypothesis from the Women's Health Initiative.

Dosing examples:

• Estradiol patch 0.05 mg/day (Vivelle-Dot, Climara) applied twice weekly or weekly
• Oral estradiol 1 to 2 mg/day
• Estradiol gel 0.75 mg/day (EstroGel)

Women with an intact uterus must add a progestogen to prevent endometrial hyperplasia. Micronized progesterone 100 to 200 mg/day (Prometrium) or norethindrone acetate 0.5 to 1 mg/day are standard options. The PEPI trial (N=875) established that unopposed estrogen increases endometrial hyperplasia risk by 10 to 34-fold at 3 years, confirming the necessity of progestogen co-administration.

Non-Hormonal Prescription Options

Fezolinetant (Veozah, 45 mg daily). The FDA approved fezolinetant in May 2023 as the first neurokinin 3 receptor antagonist for vasomotor symptoms. It blocks NK3R on KNDy neurons in the arcuate nucleus, directly reducing the hypothalamic signaling responsible for hot flashes without affecting estrogen levels. In the SKYLIGHT 1 trial (N=501), fezolinetant 45 mg reduced moderate-to-severe hot flash frequency by 60% at 12 weeks versus 34% for placebo (P<0.001). This option is particularly relevant for women with hormone-receptor-positive breast cancer history or those who decline hormone therapy.

Paroxetine mesylate (Brisdelle, 7.5 mg nightly). The only FDA-approved SSRI/SNRI specifically labeled for vasomotor symptoms. In a double-blind trial (N=614), paroxetine 7.5 mg reduced hot flash frequency by 33 to 40% versus 20 to 21% for placebo. Avoid in women taking tamoxifen because paroxetine inhibits CYP2D6 and reduces tamoxifen's active metabolite (endoxifen) by approximately 65%.

Venlafaxine 37.5 to 75 mg/day. A common off-label choice with randomized trial evidence showing a 37 to 61% reduction in hot flash composite scores. Preferred over paroxetine in tamoxifen users because venlafaxine has minimal CYP2D6 inhibition.

Gabapentin 300 mg three times daily. Reduces hot flash frequency by approximately 45% in randomized controlled trials. Particularly useful when sleep disruption is the dominant complaint, given its sedating properties.

Clonidine 0.1 mg twice daily. Modestly effective, with meta-analysis data showing roughly 15 to 26% reduction in frequency. Limited by side effects including dry mouth, constipation, and orthostatic hypotension.

Lifestyle and Behavioral Approaches

Lifestyle changes produce modest but real reductions in hot flash burden and are appropriate as adjuncts to medical therapy or as first-line management for mild symptoms.

Cognitive behavioral therapy (CBT). A UK MRC-funded trial (N=96) found that a 6-session CBT protocol reduced hot flash problem rating scores by 50% versus 27% in controls at 6 weeks, with effects sustained at 26 weeks. CBT does not reduce hot flash frequency but significantly reduces the distress and interference they cause.

Cooling strategies. Lowering ambient temperature, wearing moisture-wicking fabrics, and using layered bedding reduce trigger exposure. These recommendations appear in ACOG Committee Opinion 734 as non-pharmacologic first steps.

Weight loss. Every 1 kg of weight loss corresponds to a measurable reduction in vasomotor symptom frequency. The Women's Health Initiative dietary modification trial found that women who lost at least 10 lbs at 1 year were significantly more likely to eliminate hot flashes (OR 1.48, 95% CI 1.10 to 1.99).

Paced respiration. Slow abdominal breathing at 6 to 8 breaths per minute during a hot flash reduces sympathetic activation and may shorten episode duration. NIH-funded studies by Freedman and Woodward demonstrated reduced hot flash frequency with paced breathing versus muscle relaxation controls.

Isoflavones and phytoestrogens. Evidence remains inconsistent. A 2012 meta-analysis in Menopause (N=1,740 across 17 trials) found that phytoestrogen supplements reduced daily hot flash frequency by 1.3 episodes compared with placebo, a statistically significant but clinically modest difference.

Specific Populations: Tailoring the Workup and Treatment

Breast Cancer Survivors

Women with a personal history of hormone-receptor-positive breast cancer generally avoid systemic estrogen. Fezolinetant, venlafaxine, and gabapentin are the preferred options. The HABITS trial was stopped early after finding a higher rate of breast cancer events in women randomized to hormone therapy post-breast-cancer compared with controls, reinforcing this restriction.

Premature Ovarian Insufficiency (POI)

Women diagnosed with POI before age 40 require FSH confirmed above 40 IU/L on two tests 4 to 6 weeks apart. The Endocrine Society's 2015 POI guideline recommends systemic hormone therapy at standard doses until at least age 51 (the average age of natural menopause) to protect bone density, cardiovascular health, and cognitive function, not merely to treat symptoms.

Men on Androgen Deprivation Therapy

Venlafaxine 75 mg/day and medroxyprogesterone acetate 20 mg/day both show randomized evidence for reducing hot flash frequency in men on ADT. A crossover trial by Loprinzi et al. found medroxyprogesterone reduced hot flash activity scores by 83% in this population.

Creating a Personal Hot Flash Action Plan

A structured approach moves from diagnosis to treatment efficiently.

Step 1. Complete the lab panel (FSH, LH, E2, TSH, fasting glucose, CBC) on day 2 or 3 of the cycle if still cycling, or at any time if amenorrheic for 3 or more months.

Step 2. Track hot flash frequency and severity for 2 weeks using the validated Hot Flash Related Daily Interference Scale (HFRDIS) before the first clinical visit. A score of 5 or above on any item signals moderate-to-severe impact warranting pharmacologic treatment.

Step 3. Stratify by contraindications: personal history of hormone-receptor-positive breast cancer, active or recent venous thromboembolism, unexplained vaginal bleeding, or active liver disease each rule out systemic estrogen as a first-line choice.

Step 4. For women without contraindications and within 10 years of menopause onset or under age 60, offer transdermal estradiol 0.05 mg/day with micronized progesterone 200 mg/day (cyclic or continuous depending on uterine status).

Step 5. Reassess at 4 to 8 weeks. Symptom journals showing fewer than 5 moderate-to-severe hot flashes per day represent a treatment success threshold based on FDA guidance for vasomotor symptom endpoints.

Step 6. For non-responders or those who choose non-hormonal therapy, fezolinetant 45 mg daily is now the most targeted non-hormonal mechanism available, with a number needed to treat of approximately 6 for a 50% reduction in hot flash frequency based on SKYLIGHT 1 data.

Retest FSH and estradiol at 3 months if the diagnosis remains unclear or symptoms worsen despite treatment. An FSH that rises above 40 IU/L on repeat testing in a woman still having occasional periods confirms the perimenopausal-to-menopausal transition.